Ann: ResApp Successfully Completes $7.5 Million Capital Raising, page-3

With the completion of SMARTCOUGH-C-2, the final stage of our headline acute diagnosis clinical program, due imminently, we can now build momentum and rapidly advance multiple projects in multiple markets,” added Tony Keating, CEO and Managing Director. “The funds raised this week will accelerate the commercialisation of ResAppDx in several continents, and, by investigating new ways our unique technology can be more broadly applicable, build on our position as the world’s leading digital health company focused on respiratory disease.”